scholarly journals Endoscopic Diagnostic System Using Autofluorescence

1999 ◽  
Vol 5 (2) ◽  
pp. 59-63 ◽  
Author(s):  
S. Takehana ◽  
M. Kaneko ◽  
H. Mizuno
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Imaging System ◽  
Diagnostic System ◽  
Accurate Diagnosis ◽  
Optical Diagnostic ◽  
The Us ◽  
Fluorescence Imaging System ◽  
Diagnostic Technology ◽  
Diagnosis Of Lung Cancer

A fluorescence imaging system (Xillix LIFE – Lung Fluorescence Endoscopy system) using fluorescence for the accurate diagnosis and early detection of lesions through an endosocope has been developed. This system has applied an optical diagnostic technology to functionally diagnose lesions which have been difficult to morphologically recognize or are occult with conventional endoscope. The benefit of this system in the diagnosis of lung cancer has already been confirmed in the US and Japan, and feasibility of the system in the gastric intestinal field has also been evaluated.

scholarly journals Role of minimal panel immunostaining in accurate diagnosis of lung cancer using small biopsies

2017 ◽  
Vol 66 (2) ◽  
pp. 307-312
Author(s):  
Manar Ahmed Abdel Rahman ◽  
Nadia Abdel Moneim Nada ◽  
Khaled Refaat Zalata ◽  
Mohammad Khairy El Badrawy ◽  
Iman Mohammed El Salkh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Accurate Diagnosis ◽  
Diagnosis Of Lung Cancer

scholarly journals The continuum of screening and early detection, awareness and faster diagnosis of lung cancer

Thorax ◽  
2018 ◽  
Vol 73 (12) ◽  
pp. 1097-1098 ◽  
Author(s):  
Michael D Peake ◽  
Neal Navani ◽  
David R Baldwin
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Diagnosis Of Lung Cancer ◽  
The Continuum

scholarly journals Biomarkers and Lung Cancer Early Detection: State of the Art

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3919
Author(s):  
Elisa Dama ◽  
Tommaso Colangelo ◽  
Emanuela Fina ◽  
Marco Cremonesi ◽  
Marinos Kallikourdis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Liquid Biopsy ◽  
Therapy Response ◽  
Multimodality Treatment ◽  
Screening Programs ◽  
Lung Cancer Diagnosis ◽  
Cancer Early Detection ◽  
Monitoring Therapy ◽  
Diagnosis Of Lung Cancer

Lung cancer burden is increasing, with 2 million deaths/year worldwide. Current limitations in early detection impede lung cancer diagnosis when the disease is still localized and thus more curable by surgery or multimodality treatment. Liquid biopsy is emerging as an important tool for lung cancer early detection and for monitoring therapy response. Here, we reviewed recent advances in liquid biopsy for early diagnosis of lung cancer. We summarized DNA- or RNA-based biomarkers, proteins, autoantibodies circulating in the blood, as well as circulating tumor cells (CTCs), and compared the most promising studies in terms of biomarkers prediction performance. While we observed an overall good performance for the proposed biomarkers, we noticed some critical aspects which may complicate the successful translation of these biomarkers into the clinical setting. We, therefore, proposed a roadmap for successful development of lung cancer biomarkers during the discovery, prioritization, and clinical validation phase. The integration of innovative minimally invasive biomarkers in screening programs is highly demanded to augment lung cancer early detection. 

scholarly journals Application of Circulating Genetically Abnormal Cells in the Early-stage Diagnosis of Lung Cancer

2021 ◽  
Author(s):  
xiaochang qiu ◽  
haoran Zhang ◽  
yongheng Zhao ◽  
yunyan Wan ◽  
dezhi Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Early Diagnosis ◽  
Lung Disease ◽  
Roc Curve ◽  
Early Detection Of Disease ◽  
Non Invasive ◽  
Imaging Characteristics ◽  
Abnormal Cells ◽  
Diagnosis Of Lung Cancer

Abstract Background Lung cancer is the primary cause of cancer related death worldwide, early detection of the disease contributes to early diagnosis and reduce the incidence of death from lung cancer. Therefore, an effective and non-invasive method for early diagnosis of lung cancer is urgently needed.Methods To evaluate the diagnostic performance of circulating genetically abnormal cells(CAC) in early lung cancer, a total of 63 participants who completed CAC detection by ZHUHAI SANMED BIOTECH INC. and obtained pathological results from January to December 2020 were included in our study, which were divided into 50 cases of lung cancer ,13 cases of benign lung disease. The levels of lung cancer-related markers in peripheral blood and chest computed tomography(CT) imaging characteristics of these patients were collected before pathological acquisition.Results The positive rate of CAC was 90.0% in lung cancer group and 23.1% in benign lung disease group, the difference was statistically significant (P＜0.01).The area under the receiver operating characteristic (ROC) curve of CAC was 0.837, the sensitivity was 90%, and the specificity was 76.9%.The area under the ROC curve and sensitivity were both higher than the combined or single serum tumor marker test.Conclusions This study preliminarily concludes that CAC, as a non-invasive test, has high sensitivity and specificity for early diagnosis of lung cancer, which is expected to help early detection of disease in lung cancer patients and has certain help and guiding significance for clinical work.

scholarly journals CD24+/CD38- as new prognostic marker for non-small cell lung cancer

2013 ◽  
Vol 8 ◽  
Author(s):  
Feridoun Karimi-Busheri ◽  
Aghdass Rasouli-Nia ◽  
Victoria Zadorozhny ◽  
Habib Fakhrai
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Detection And Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
New Biomarkers

Background: Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods: In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results: We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions: We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.

Sign in / Sign up

Export Citation Format

Share Document